1. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999; 353:878–882. PMID:
10093980.
Article
2. Park EJ, Joo IW, Jang MJ, Kim YT, Oh K, Oh HJ. Prevalence of osteoporosis in the Korean population based on Korea National Health and Nutrition Examination Survey (KNHANES), 2008-2011. Yonsei Med J. 2014; 55:1049–1057. PMID:
24954336.
Article
3. Nam GE, Han K, Park YG, Kim YH, Han B, Kim SM, et al. Prevalence and related risk factors of albuminuria in Korean adults: the 2011 Korea National Health and Nutrition Examination Survey. Nephron Clin Pract. 2013; 124:232–238. PMID:
24503631.
Article
4. Glassock RJ. Is the presence of microalbuminuria a relevant marker of kidney disease? Curr Hypertens Rep. 2010; 12:364–368. PMID:
20686930.
Article
5. de Zeeuw D, Parving HH, Henning RH. Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol. 2006; 17:2100–2105. PMID:
16825327.
Article
6. Gupta J, Mitra N, Kanetsky PA, Devaney J, Wing MR, Reilly M, et al. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol. 2012; 7:1938–1946. PMID:
23024164.
Article
7. Hagstromer M, Oja P, Sjostrom M. The International Physical Activity Questionnaire (IPAQ): a study of concurrent and construct validity. Public Health Nutr. 2006; 9:755–762. PMID:
16925881.
8. Sheng CS, Hu BC, Fan WX, Zou J, Li Y, Wang JG. Microalbuminuria in relation to the metabolic syndrome and its components in a Chinese population. Diabetol Metab Syndr. 2011; 3:6. PMID:
21470432.
Article
9. Palaniappan L, Carnethon M, Fortmann SP. Association between microalbuminuria and the metabolic syndrome: NHANES III. Am J Hypertens. 2003; 16(11 Pt 1):952–958. PMID:
14573334.
Article
10. van der Velde M, Bello AK, Brantsma AH, El Nahas M, Bakker SJ, de Jong PE, et al. Do albuminuria and hs-CRP add to the International Diabetes Federation definition of the metabolic syndrome in predicting outcome? Nephrol Dial Transplant. 2012; 27:2275–2283. PMID:
22231032.
Article
11. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998; 15:539–553. PMID:
9686693.
Article
12. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001; 285:2486–2497. PMID:
11368702.
13. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 1999; 16:442–443. PMID:
10342346.
14. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005; 365:1415–1428. PMID:
15836891.
Article
15. Kim HY, Choe JW, Kim HK, Bae SJ, Kim BJ, Lee SH, et al. Negative association between metabolic syndrome and bone mineral density in Koreans, especially in men. Calcif Tissue Int. 2010; 86:350–358. PMID:
20354685.
Article
16. Kim T, Park S, Pak YS, Lee S, Lee EH. Association between metabolic syndrome and bone mineral density in Korea: the Fourth Korea National Health and Nutrition Examination Survey (KNHANES IV), 2008. J Bone Miner Metab. 2013; 31:652–662. PMID:
23543212.
Article
17. Hwang DK, Choi HJ. The relationship between low bone mass and metabolic syndrome in Korean women. Osteoporos Int. 2010; 21:425–431. PMID:
19565174.
Article
18. Szulc P, Varennes A, Delmas PD, Goudable J, Chapurlat R. Men with metabolic syndrome have lower bone mineral density but lower fracture risk: the MINOS study. J Bone Miner Res. 2010; 25:1446–1454. PMID:
20200928.
19. Rosen CJ, Bouxsein ML. Mechanisms of disease: is osteoporosis the obesity of bone? Nat Clin Pract Rheumatol. 2006; 2:35–43. PMID:
16932650.
Article
20. Lazarenko OP, Rzonca SO, Hogue WR, Swain FL, Suva LJ, Lecka-Czernik B. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology. 2007; 148:2669–2680. PMID:
17332064.
Article
21. Gimble JM, Robinson CE, Wu X, Kelly KA, Rodriguez BR, Kliewer SA, et al. Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol. 1996; 50:1087–1094. PMID:
8913339.
22. Tanna N, Patel K, Moore AE, Dulnoan D, Edwards S, Hampson G. The relationship between circulating adiponectin, leptin and vaspin with bone mineral density (BMD), arterial calcification and stiffness: a cross-sectional study in post-menopausal women. J Endocrinol Invest. 2017; 40:1345–1353. PMID:
28646476.
Article
23. Elefteriou F, Takeda S, Ebihara K, Magre J, Patano N, Kim CA, et al. Serum leptin level is a regulator of bone mass. Proc Natl Acad Sci U S A. 2004; 101:3258–3263. PMID:
14978271.
Article
24. Lecka-Czernik B. Marrow fat metabolism is linked to the systemic energy metabolism. Bone. 2012; 50:534–539. PMID:
21757043.
Article
25. Kawai M, de Paula FJ, Rosen CJ. New insights into osteoporosis: the bone-fat connection. J Intern Med. 2012; 272:317–329. PMID:
22702419.
Article
26. Jilka RL, Hangoc G, Girasole G, Passeri G, Williams DC, Abrams JS, et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science. 1992; 257:88–91. PMID:
1621100.
Article
27. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med. 1995; 332:305–311. PMID:
7816067.
28. Nanes MS. Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology. Gene. 2003; 321:1–15. PMID:
14636987.
29. Salamone LM, Whiteside T, Friberg D, Epstein RS, Kuller LH, Cauley JA. Cytokine production and bone mineral density at the lumbar spine and femoral neck in premenopausal women. Calcif Tissue Int. 1998; 63:466–470. PMID:
9817939.
Article
30. Scheidt-Nave C, Bismar H, Leidig-Bruckner G, Woitge H, Seibel MJ, Ziegler R, et al. Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause. J Clin Endocrinol Metab. 2001; 86:2032–2042. PMID:
11344203.
Article
31. Choi SW, Kim HY, Ahn HR, Lee YH, Kweon SS, Choi JS, et al. Association of bone mineral density with albuminuria and estimated glomerular filtration rate: the Dong-gu Study. Kidney Blood Press Res. 2013; 37:132–141. PMID:
23615166.
32. Barzilay JI, Gao P, Clase CM, Mente A, Mann JF, Sleight P, et al. Albuminuria and rapid loss of GFR and risk of new hip and pelvic fractures. Clin J Am Soc Nephrol. 2013; 8:233–240. PMID:
23184565.
Article
33. Kim BJ, Ahn SH, Bae SJ, Kim EH, Kim TH, Lee SH, et al. Association between metabolic syndrome and bone loss at various skeletal sites in postmenopausal women: a 3-year retrospective longitudinal study. Osteoporos Int. 2013; 24:2243–2252. PMID:
23389696.
Article
34. Ahmed LA, Schirmer H, Berntsen GK, Fonnebo V, Joakimsen RM. Features of the metabolic syndrome and the risk of non-vertebral fractures: the Tromso study. Osteoporos Int. 2006; 17:426–432. PMID:
16437192.